Virtual screening studies to design potent CDK2-cyclin A inhibitors
S Vadivelan1, Barij Nayan Sinha, Sheeba Jem Irudayam
1GVK Biosciences Pvt. Ltd. S-1, Phase-1, T.I.E. Balanagar, Hyderabad-500037, India. vadivelan@gvkbio.com
Journal of Chemical Information and Modeling
|May 26, 2007
Summary
Researchers identified key features for cyclin-dependent kinase (CDK) inhibitors, crucial for controlling the cell division cycle. Pharmacophore and docking studies revealed essential hydrogen bond and hydrophobic interactions for designing potent CDK2-cyclin A inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Medicinal Chemistry
Background:
- The cell division cycle is regulated by cyclin-dependent kinases (CDKs), comprising catalytic (CDK1-CDK8) and regulatory (cyclin A-H) subunits.
- Dysregulation of CDKs is implicated in various diseases, making them important therapeutic targets.
Purpose of the Study:
- To develop a predictive pharmacophore model for cyclin-dependent kinase (CDK) inhibitors.
- To explore structural requirements for CDK2-cyclin A inhibitors using docking studies.
- To identify novel potent CDK2-cyclin A inhibitors through virtual screening.
Main Methods:
- Pharmacophore modeling using HypoRefine to define inhibitor features.
- Molecular docking studies to analyze inhibitor-receptor interactions.
- Virtual screening of a molecular library to identify potential hits.
Main Results:
- The optimal pharmacophore model features two hydrogen bond acceptors, one hydrogen bond donor, and one hydrophobic feature.
- Docking studies confirmed the significance of hydrogen bonding and hydrophobic interactions for binding affinity.
- The validated model successfully identified potent lead compounds from a virtual library.
Conclusions:
- Pharmacophore modeling and docking are effective strategies for designing CDK inhibitors.
- Understanding key interactions can guide the development of novel therapeutic agents targeting CDK2-cyclin A.
- This study provides a foundation for the rational design of new CDK inhibitors.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.